FDA approves new diagnostic imaging agent to detect recurrent prostate cancer - FDA Press Releases

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment.

from Food and Drug Administration--Press Releases http://ift.tt/1TEXatq
via IFTTT